Stryker Corporation $SYK Stock Sold by Harbour Investments Inc.

Harbour Investments Inc. decreased its position in shares of Stryker Corporation (NYSE:SYK – Free Report) by 21.8% in the third quarter, HoldingsChannel reports. The fund owned 19,277 shares of the medical technology company’s stock after selling 5,370 shares during the quarter. Harbour Investments Inc.’s holdings in Stryker were worth $5,309,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Bank of America Corp DE acquired a new position in shares of Stryker during the second quarter worth $1,404,284,000. Legal & General Group Plc acquired a new position in Stryker during the 2nd quarter valued at about $707,212,000. Jupiter Topco LLC acquired a new position in Stryker during the 2nd quarter valued at about $681,581,000. Corient Private Wealth LP purchased a new stake in Stryker in the second quarter valued at about $323,035,000. Finally, Flossbach Von Storch SE purchased a new stake in Stryker in the second quarter valued at about $464,506,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

SYK has been the topic of several recent analyst reports. Sanford C. Bernstein restated a “market perform” rating on shares of Stryker in a report on Wednesday, October 7th. Deutsche Bank decreased their price objective on shares of Stryker from $315.00 to $275.00 and set a “hold” rating for the company in a research report on Friday, October 30th. Wall Street Zen downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Barclays reduced their target price on Stryker from $375.00 to $365.00 and set an “overweight” rating for the company in a research note on Friday, October 30th. Finally, Needham & Company LLC lowered their price target on Stryker from $418.00 to $359.00 and set a “buy” rating for the company in a research report on Friday, October 30th. Twenty-one equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $342.19.

Read Our Latest Report on Stryker

Insider Transactions at Stryker

In other news, insider Dylan Crotty sold 441 shares of the company’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the sale, the insider owned 6,102 shares in the company, valued at $2,005,178.22. This represents a 6.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ronda E. Stryker sold 550,000 shares of the firm’s stock in a transaction dated Friday, November 6th. The stock was sold at an average price of $325.32, for a total value of $178,926,000.00. Following the sale, the director directly owned 1,701,375 shares in the company, valued at approximately $553,491,315. This trade represents a 24.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 600,441 shares of company stock valued at $196,075,917 in the last quarter. Company insiders own 4.60% of the company’s stock.

Stryker Stock Performance

Shares of NYSE SYK opened at $310.30 on Tuesday. The company has a 50 day simple moving average of $292.44 and a two-hundred day simple moving average of $322.36. The stock has a market cap of $118.13 billion, a price-to-earnings ratio of 21.88, a PEG ratio of 2.14 and a beta of 0.78. The company has a current ratio of 2.18, a quick ratio of 1.30 and a debt-to-equity ratio of 0.60. Stryker Corporation has a 12 month low of $267.00 and a 12 month high of $389.33.

Stryker (NYSE:SYK – Get Free Report) last issued its earnings results on Thursday, October 29th. The medical technology company reported $3.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.55 by ($0.03). The business had revenue of $6.52 billion for the quarter, compared to analysts’ expectations of $6.62 billion. Stryker had a return on equity of 23.74% and a net margin of 13.78%. The company’s revenue for the quarter was up 7.6% on a year-over-year basis. During the same period last year, the business earned $3.19 EPS. As a group, analysts predict that Stryker Corporation will post 14.85 earnings per share for the current year.

About Stryker

(Free Report)

Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings. The company’s products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.

Recommended Stories

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.